1. What Is the Heart Failure Drug Market?
The Heart Failure Drug Market covers pharmacological therapies for systolic and diastolic heart failure including GDMT combinations, novel mechanism agents, and HFpEF-specific treatments. Heart failure drug encompasses ARNI sacubitril-valsartan, SGLT2 inhibitors, GLP-1 receptor agonists for HFpEF, beta-blockers, MRAs, and investigational HFpEF precision medicine targets. Market dynamics reflect quadruple GDMT therapy achieving guideline consensus recommendation, HFpEF emerging pharmacological treatment creating new commercial category, and heart failure drug adherence improvement tools reducing hospitalisation.
2. Heart Failure Drug Market Size & Forecast
3. Emerging Technologies
- Aldosterone synthase inhibitor lorundrostat Phase 3 trials for resistant hypertension and HF cardiorenal protection are advancing. Growing investment is driven by finerenone MRA success model and cardiorenal protection requirements.
- Mavacamten myosin inhibitor expanding from HCM into HFpEF clinical trials are advancing as HFpEF-specific mechanism tools. Growing clinical investment is driven by HFpEF functional improvement requirements beyond GLP-1.
- Iron deficiency correction with IV ferric carboxymaltose demonstrating 16 percent HF hospitalisation reduction are advancing as supportive therapy. Growing adoption at HF clinics is driven by iron-deficient HF patient symptom improvement requirements.
- Soluble guanylate cyclase stimulator vericiguat in high-risk HFrEF are advancing as add-on therapy tools. Growing adoption is driven by post-hospitalisation high-risk HF patient treatment gap requirements.
Such innovations are driving change across adjacent industries too. Discover more in our Cardiovascular Drug Market.
4. Key Market Opportunity
Revenue is concentrated in the Heart Failure Drug Market at the HFpEF GLP-1 receptor agonist sub-market, where tirzepatide SURMOUNT-HF creates a new pharmacotherapy category for the 50 percent of HF patients with preserved ejection fraction. ARNI Entresto creates a sustained premium revenue channel as guideline first-pillar status maintains long-term commercial dominance. SGLT2 inhibitor HF creates a high-volume generic competition opportunity as dapagliflozin and empagliflozin face biosimilar pressure. Asia Pacific HF drug creates geographic expansion as Chinese and Japanese HF programme GDMT adoption grows.
5. Top Companies in the Heart Failure Drug Market
The following organisations hold leading positions in the Heart Failure Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Novartis (Entresto ARNI)
- AstraZeneca (Farxiga SGLT2)
- Boehringer Ingelheim (Jardiance SGLT2)
- Eli Lilly (Tirzepatide HFpEF)
- Bristol-Myers (Vericiguat)
- Bayer (Finerenone)
- Merck (Carvedilol generic)
- AstraZeneca (Bisoprolol generic)
- Cytokinetics (Omecamtiv Mecarbil)
- Karuna (Cardiac)
6. Market Segmentation
The Heart Failure Drug Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | ARNI SGLT2 Beta-Blocker MRA GLP-1 Vericiguat |
| By HF Subtype | HFrEF EF Below 40% HFmrEF 40-49% HFpEF EF Above 50% |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Heart Failure Drug Market trajectory over the forecast period:
Novartis Entresto ARNI Achieves USD 4.7 Billion Annual Revenue as GDMT First Pillar Leader.Novartis sacubitril-valsartan Entresto achieving USD 4.7 billion annual revenue in 2024 demonstrates ARNI as the commercial pillar of HFrEF GDMT pharmacotherapy. PARADIGM-HF trial demonstrating 20 percent cardiovascular death reduction versus enalapril establishes Entresto as guideline first-line ARNI therapy across all HFrEF patients.
SGLT2 Inhibitors Achieve Guideline Fourth Pillar GDMT Status With USD 5 Billion Combined HF Revenue.AstraZeneca dapagliflozin and Boehringer Ingelheim empagliflozin achieving combined USD 5 billion annual HF revenue in 2024 demonstrate SGLT2 class establishing as guideline-recommended fourth GDMT pillar. DAPA-HF and EMPEROR-Reduced demonstrating 25 percent worsening HF and cardiovascular death reduction establish the SGLT2 class HFrEF benefit.
Eli Lilly Tirzepatide SURMOUNT-HF Data Positions GLP-1 as First HFpEF Pharmacotherapy.Eli Lilly tirzepatide achieving 38 percent 6-minute walk improvement and 50 percent HF hospitalisation reduction in obese HFpEF patients in SURMOUNT-HF 2024 trial demonstrates the first effective pharmacotherapy for HFpEF. HFpEF representing 50 percent of all HF patients with no prior standard pharmacotherapy creates a new commercial category for GLP-1 in heart failure.
For related market intelligence, see the Heart Failure Management Market.
8. Segmental Analysis
By drug class, the SGLT2 Inhibitor segment dominated the Heart Failure Drug Market in 2025 by combined HFrEF and HFpEF revenue with dapagliflozin and empagliflozin commercial breadth. The GLP-1 Receptor Agonist HFpEF segment is the fastest-growing category, advancing as tirzepatide SURMOUNT-HF creates a new HFpEF pharmacotherapy commercial opportunity.
By subtype, the HFrEF segment dominated the Heart Failure Drug Market in 2025. Representing the largest type revenue share. The HFpEF segment is the fastest-growing type category, advancing as from near-zero baseline. Revenue diversification across type reflects the range of buyer segments and procurement approaches within the Heart Failure Drug Market.
By HF subtype, the HFrEF segment dominated the Heart Failure Drug Market in 2025, as guideline-directed quadruple medical therapy for reduced ejection fraction heart failure drives the majority of heart failure drug revenue globally. HFpEF is the fastest-growing subtype category, driven by SGLT2 inhibitor approval for preserved ejection fraction and growing physician recognition and treatment of the HFpEF phenotype in ageing populations.
9. Regional Analysis
Regional demand patterns across the Heart Failure Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Heart Failure Drug Market in 2025, holding 44.9% of the global market. Cardiologists, heart failure specialists, and health systems are deploying heart failure pharmacotherapy including SGLT2 inhibitors, sacubitril/valsartan, and ivabradine to manage both HFrEF and HFpEF patient populations. FDA heart failure drug approvals for novel drug classes and CMS coverage for guideline-directed heart failure medical therapy are encouraging cardiologists and primary care physicians to optimise heart failure pharmacotherapy. High heart failure prevalence, growing physician awareness of novel therapy benefits, and strong pharmaceutical investment in heart failure are generating strong regional demand.
Highest CAGR Region
Europe is expected to register the highest CAGR of 9.42% during the forecast period. Cardiologists and heart failure specialists across Germany, France, Italy, Spain, and the Netherlands are deploying SGLT2 inhibitors, sacubitril/valsartan, and other novel heart failure therapies as European clinical guideline updates drive prescribing behaviour. European Society of Cardiology heart failure guideline recommendations and growing cardiovascular specialist adoption of quadruple heart failure therapy are generating prescribing growth. Rising heart failure prevalence, increasing pharmaceutical investment in heart failure pharmacotherapy, and growing awareness of mortality benefit from novel drug classes are generating European demand.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Heart Failure Drug Market was valued at USD 22.48 Bn in 2025 and is projected to reach USD 43.11 Bn by 2034, growing at a CAGR of 7.5% over the 2026–2034 forecast period.
The Heart Failure Drug Market is projected to grow at a CAGR of 7.5% from 2026 to 2034.
North America accounted for the largest share of the Heart Failure Drug Market in 2025, holding 44.9% of the global market.
The leading companies in the Heart Failure Drug Market include Novartis (Entresto ARNI), AstraZeneca (Farxiga SGLT2), Boehringer Ingelheim (Jardiance SGLT2), Eli Lilly (Tirzepatide HFpEF), Bristol-Myers (Vericiguat), Bayer (Finerenone), Merck (Carvedilol generic), AstraZeneca (Bisoprolol generic), Cytokinetics (Omecamtiv Mecarbil), Karuna (Cardiac).
Novartis entresto arni achieves usd 4.7 billion annual revenue as gdmt first pillar leader.
By drug class, the SGLT2 Inhibitor segment dominated the Heart Failure Drug Market in 2025 by combined HFrEF and HFpEF revenue with dapagliflozin and empagliflozin commercial breadth.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.